McMaster Health Sciences Centre
Hamilton, Ontario, L8N3Z5, Canada
NCT Number: NCT03059862
This study evaluates the role of dietary L-tryptophan, an essential amino acid, in the activation of a specific cellular component: the aryl hydrocarbon receptor.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Hamilton, Ontario, L8N3Z5, Canada
The Aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor implicated in a range of key cellular events. In the gut, AHR is crucial for maintaining intestinal barrier immune homeostasis. The physiology of the AHR, however, is not completely understood; its precise gut luminal activators and functional consequences are unknown.
Some AHR ligands originate from the diet. Commensals play crucial roles in metabolizing tryptophan and other amino acids such as tyrosine, with the subsequent production of tryptophan metabolites. Previous studies show that inflammatory bowel disease (IBD) patients have impaired production of AHR agonists by the microbiota. Furthermore, dietary supplementation with tryptophan ameliorates clinical parameters of colitis in rodent models. Whether these findings translate into human pathophysiology has not been explored.
In the present study, the investigators will evaluate the effect of high- versus low-tryptophan diet on AHR activation in healthy participants. Briefly, participants will be instructed to follow a standardized low-tryptophan diet and will be randomized to a 3-week L-tryptophan supplement or placebo. Later, after a 2-week washout period, participants will crossover to the other arm. In addition, the effect of tryptophan and microbiota-derived metabolites on AHR activation will be analyzed.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
Time frame: three weeks
Changes in AHR activation levels will be assessed in stool and duodenal samples before and after the intervention (high- and low-tryptophan diets) using an AHR cell-reporter line.
Time frame: Three weeks
Changes in bacterial and fungal microbiota composition will be assessed before and after the intervention in stool samples, duodenum and rectum biopsies.
Time frame: Three weeks
Changes in tryptophan metabolites leves will be compared before and after the intervention, in blood, urine and stool samples.
Time frame: three weeks
Changes in mRNA levels in duodenal and rectum/sigmoid biopsies will be assessed before and after the intervention.
Time frame: three weeks.
Changes in cytokines in the serum (IL-22, IL-6, IL-2, IL-10, IL-12p70, IL-23p19, IFNγ, TNFα and CRP will be measured by ELISA in cell culture supernatants after stimulation with LPS, curdlan and ConA ) will be measured before and after the intervention and patients will be grouped into two categories for each measurement: high vs. low, according to the cutoff reference test value for each of the cytokines.
Time frame: three weeks.
Changes in gastrointestinal symptoms before and after the intervention will be assessed using a validated questionnaire (The Gastrointestinal Symptoms Rating Scale)
Time frame: three weeks
Changes in mood before and after the intervention will be assessed using a validated questionnaire (Hospital anxiety and depression scale)
McMaster University
Other
The Role of Tryptophan on Aryl Hydrocarbon Receptor Activation: a Randomized, Double Blind, Placebo-controlled, Crossover Design Pilot Trial
Acronym: Aryl-IMMUNE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03678935
Celiac Disease, Colonic Diseases
Oslo, Postboks PB 4950 Nydalen, Norway
View Trial DetailsNCT03874988
Body Weight, Body Weight Changes
Dallas, Texas, United States
View Trial DetailsNCT03994055
Adnexal Diseases, Cervical Cancer
Mexico City, Mexico
View Trial DetailsNCT03499509
Diet Modification
Birmingham, Alabama, United States
View Trial Details